Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test
- PMID: 28327117
- PMCID: PMC5361708
- DOI: 10.1186/s12906-017-1665-8
Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test
Abstract
Background: Alternative treatment strategies have become essential in overcoming the problem of drug-resistant Mycobacterium tuberculosis (Mtb). In this preliminary in vitro study, the anti-tuberculosis (anti-TB) activity of exogenous iron chelators (xenosiderophores) such as Exochelin-MS (Exo-MS) and Deferoxamine-B (DFO-B) was evaluated against ten multi-drug-resistant (MDR) and seven pyrazinamide-resistant (PZA R ) Mtb isolates.
Methods: Mycobacteria Growth Indicator Tube-Drug Susceptibility Test was used to assess the anti-TB effect of Exo-MS or DFO-B individually and their combinations with isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA).
Results: For the MDR-Mtb isolates, Exo-MS alone inhibited two out of the five isolates tested. Whereas, DFO-B alone inhibited nine out of the ten MDR isolates tested. For PZA-resistant Mtb isolates, both Exo-MS and DFO-B individually inhibited five out of the seven isolates. The MIC of Exo-MS in combination with INH, RIF and PZA remained the same. The MIC of DFO-B decreased when tested in combination with INH, RIF and PZA.
Conclusions: Exo-MS and DFO-B were shown to have activity against drug-resistant Mtb isolates. Therefore, these xenosiderophores may be useful adjuncts to antibiotics in overcoming the problem of drug-resistant Mtb in clinical setting.
Keywords: Deferoxamine-B; Exochelin-MS; Mycobacteria growth indicator tube-drug sensitivity test; Tuberculosis; Xenosiderophores.
Similar articles
-
Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.Tuberculosis (Edinb). 2016 Dec;101:137-143. doi: 10.1016/j.tube.2016.09.006. Epub 2016 Sep 22. Tuberculosis (Edinb). 2016. PMID: 27865383
-
[Multicenter evaluation of the indirect nitrate reductase assay for the rapid detection of multidrug-resistant tuberculosis].Mikrobiyol Bul. 2016 Jan;50(1):140-6. doi: 10.5578/mb.10339. Mikrobiyol Bul. 2016. PMID: 27058338 Turkish.
-
Drug resistance in Mycobacterium tuberculosis clinical isolates from Brazil: phenotypic and genotypic methods.Biomed Pharmacother. 2011 Sep;65(6):456-9. doi: 10.1016/j.biopha.2011.04.021. Epub 2011 Jun 12. Biomed Pharmacother. 2011. PMID: 21880463
-
A Note on Derivatives of Isoniazid, Rifampicin, and Pyrazinamide Showing Activity Against Resistant Mycobacterium tuberculosis.Chem Biol Drug Des. 2016 Apr;87(4):537-50. doi: 10.1111/cbdd.12684. Epub 2016 Jan 17. Chem Biol Drug Des. 2016. PMID: 26613382 Review.
-
QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.Curr Pharm Des. 2014;20(27):4427-54. doi: 10.2174/1381612819666131118164434. Curr Pharm Des. 2014. PMID: 24245762 Review.
Cited by
-
Activity of siderophores against drug-resistant Gram-positive and Gram-negative bacteria.Infect Drug Resist. 2018 Jan 9;11:61-75. doi: 10.2147/IDR.S148602. eCollection 2018. Infect Drug Resist. 2018. PMID: 29386910 Free PMC article.
-
Targeting Mycobacterium tuberculosis iron-scavenging tools: a recent update on siderophores inhibitors.RSC Med Chem. 2023 Sep 6;14(10):1885-1913. doi: 10.1039/d3md00201b. eCollection 2023 Oct 18. RSC Med Chem. 2023. PMID: 37859726 Free PMC article. Review.
-
High Glucose and Carbonyl Stress Impair HIF-1-Regulated Responses and the Control of Mycobacterium tuberculosis in Macrophages.mBio. 2022 Oct 26;13(5):e0108622. doi: 10.1128/mbio.01086-22. Epub 2022 Sep 19. mBio. 2022. PMID: 36121152 Free PMC article.
References
-
- WHO updates 2015. http://www.who.int/mediacentre/factsheets/fs194/en/.
-
- WHO updates 2016. http://www.who.int/mediacentre/news/releases/2016/multidrug-resistant-tu....
-
- Siddiqi SH, Rüsch-Gerdes S. Foundation for Innovative New Diagnostics (FIND) Geneva: MGIT procedure manual; 2006.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources